Concepedia

Author

Madhu Sanga

Massachusetts General Hospital

Also Known As

M P Sanga, M SANGA, M Sanga, Madhu Sanga

19

Publications

184

Citations

7

H-Index

15

Concepts

All Affiliations

Massachusetts General HospitalThe Christie NHS Foundation TrustJanssen (United States)Hospital Clínic de BarcelonaInstitut universitaire du cancer de Toulouse Oncopole
MS

About

Madhu Sanga is an author at Massachusetts General Hospital specializing in pharmacology, toxicology, and biochemistry.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Pharmacology

2

2

28

2

Health Sciences

1

1

18

3

Medicine

1

1

18

4

Biochemistry

1

1

10

5

Metabolism

1

1

18

Madhu Sanga

×

7

Publications

162

Citations

7

H-Index

YearCitations

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Elias Jabbour, Emma Searle, Maher Abdul‐Hay,

Blood

2023

42

An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia

Madhu Sanga, Joyce James, Joseph Marini,

Xenobiotica

2016

31

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations

Emma Searle, Christian Récher, Maher Abdul‐Hay,

Blood

2024

25

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss,

Blood

2024

21

Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers

Madhu Sanga, John Banach, Aaron R. Ledvina,

Xenobiotica

2016

18

Absorption, Metabolism, and Excretion of [<sup>14</sup>C]‐Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open‐Label, Mass‐Balance Study

Monette Cotreau, Christine Hale, Lindsey Jacobson,

Clinical Pharmacology in Drug Development

2012

15

Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation☆

Madhu Sanga, Islam R. Younis, Padmashree S. Tirumalai,

Toxicology and Applied Pharmacology

2005

10

Page 1